Open Nav

Please submit your session questions in advance at

Advances in Neuromuscular Disease Treatments

After a long era without progress, recent years have seen regulatory approvals of treatments for Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), among other neuromuscular disorders. In particular, SMA is the most common genetic disorder leading to infant death in the world, and now has a first therapy that can slow disease progression, giving patients and families more time together. This session will examine the exciting pipeline of additional neuromuscular disease therapies, and what the underlying science is teaching across disease indications, amid a complicated reimbursement context where the shortage of effective treatments bears significant healthcare costs over time.

Moderator: Lynn O'Connor Vos, President and CEO, Muscular Dystrophy Association (MDA)

  • Date:Monday, February 11
  • Time:11:00 AM - 11:55 AM
  • Room:Shubert Complex
  • Location:6th Floor
  • Session Type:Educational Panel
  • Please submit your session questions in advance:

    Click here.

Lynn O'Connor Vos
Muscular Dystrophy Association (MDA)
Murray Aitken
Jay A. Barth
Amicus Therapeutics
Amanda Haidet-Phillips
Muscular Dystrophy Association
Brian K. Kaspar
Nader Yaghoubi
PathMaker Neurosystems Inc.